Proposed endophenotypes of dysthymia: Evolutionary, clinical and pharmacogenomic considerations

A. B. Niculescu, H. S. Akiskal

Research output: Contribution to journalArticle

35 Scopus citations


Dysthymia is highly prevalent - though underdiagnosed - occurring in at least 3% of the population. We conceptualize it as the clinical extension of adaptive traits that have developed during evolution to cope with stress and failure. A classification of dysthymias into anxious and anergic subtypes - and their putative association to bipolarity - is proposed. We further posit neurochemical and neurophysiological substrates for the two subtypes. A better recognition and understanding of dysthymic subtypes and their respective place in the affective spectrum will increase the proportion of people that may benefit from targeted treatments. It would also expand the pool of subjects that may be enrolled in genetic and pharmacogenomic research studies.

Original languageEnglish (US)
Pages (from-to)363-366
Number of pages4
JournalMolecular Psychiatry
Issue number4
StatePublished - Jul 4 2001
Externally publishedYes


  • Dopamine
  • Dysthymia
  • Endophenotypes
  • Evolution
  • Gender
  • Genes
  • Neurasthenia
  • Pharmacogenomics
  • Serotonin

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Proposed endophenotypes of dysthymia: Evolutionary, clinical and pharmacogenomic considerations'. Together they form a unique fingerprint.

  • Cite this